HK1211593A1 - Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease - Google Patents

Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease

Info

Publication number: HK1211593A1
Authority: HK; Hong Kong
Prior art keywords: diagnostic; treatment; human antibodies; therapeutic uses; neurological disease
Prior art date: 2010-10-19

Application number

HK15112222.8A

Other languages

English (en)

Chinese (zh)

Inventor

Moses Rodriguez

Arthur E Warrington

Larry R Pease

Original Assignee

Mayo Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-19

Filing date

2015-12-11

Publication date

2016-05-27

2015-12-11 Application filed by Mayo Foundation filed Critical Mayo Foundation

2016-05-27 Publication of HK1211593A1 publication Critical patent/HK1211593A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

HK15112222.8A 2010-10-19 2015-12-11 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease HK1211593A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US45536310P	2010-10-19	2010-10-19
US201161537392P	2011-09-21	2011-09-21
US201161546634P	2011-10-13	2011-10-13

Publications (1)

Publication Number	Publication Date
HK1211593A1 true HK1211593A1 (en)	2016-05-27

Family

ID=45975788

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK15112222.8A HK1211593A1 (en)	2010-10-19	2015-12-11	Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
HK19100399.6A HK1258028A1 (zh)	2010-10-19	2019-01-10	人類抗體及其在神經疾病治療中的診斷和治療用途

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK19100399.6A HK1258028A1 (zh)	2010-10-19	2019-01-10	人類抗體及其在神經疾病治療中的診斷和治療用途

Country Status (12)

Country	Link
US (2)	US20130280167A1 (xx)
EP (2)	EP3345619A1 (xx)
JP (5)	JP6000959B2 (xx)
CN (2)	CN104725507B (xx)
AU (2)	AU2011318567B2 (xx)
BR (1)	BR112013009673B1 (xx)
CA (2)	CA2815046C (xx)
ES (1)	ES2662100T3 (xx)
HK (2)	HK1211593A1 (xx)
IL (2)	IL225837B (xx)
NZ (2)	NZ624752A (xx)
WO (1)	WO2012054077A2 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104725507B (zh) *	2010-10-19	2018-12-21	梅奥医学教育和研究基金会	用于治疗神经疾病的人抗体及其诊断和治疗用途
NZ701278A (en) *	2012-04-17	2016-12-23	Mayo Foundation	Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
EP3105250B1 (en)	2014-02-10	2020-08-05	IGM Biosciences, Inc.	Iga multi-specific binding molecules
KR20230155600A (ko)	2014-04-03	2023-11-10	아이쥐엠 바이오사이언스 인코포레이티드	변형된 j-사슬
CA2967026A1 (en) *	2014-11-07	2016-05-12	Mayo Foundation For Medical Education And Research	Treatment of neonatal hypoxia including impairments or effects thereof
KR20240135877A (ko)	2015-03-04	2024-09-12	아이쥐엠 바이오사이언스 인코포레이티드	Ｃｄ20 결합 분자 및 그의 용도
US11639389B2 (en)	2015-09-30	2023-05-02	Igm Biosciences, Inc.	Binding molecules with modified J-chain
JP7065766B2 (ja)	2015-09-30	2022-05-12	アイジーエムバイオサイエンシズインコーポレイテッド	改変ｊ鎖を有する結合分子
CN112037147B (zh) *	2020-09-02	2024-05-14	上海联影医疗科技股份有限公司	医学图像降噪方法和装置
US20240002534A1 (en) *	2020-11-30	2024-01-04	Merck Sharp & Dohme Llc	Arginase 1 binders for inhibiting arginase 1 activity
CN117679488B (zh) *	2023-12-13	2024-07-05	暨南大学附属第一医院（广州华侨医院）	纳米拮抗剂Au-ADH1在制备治疗脊髓损伤修复药物的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5776093A (en)	1985-07-05	1998-07-07	Immunomedics, Inc.	Method for imaging and treating organs and tissues
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US7473423B2 (en) *	1994-04-29	2009-01-06	Mayo Foundation For Medical Education And Research	Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6306393B1 (en)	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
PT1032674E (pt) *	1997-11-21	2007-03-30	Serono Genetics Inst Sa	Sequência genómica e polipéptidos (de chlamydia pneumoniae), seus fragmentos e suas utilizações, em particular para o diagnóstico, prevenção e tratamento de infacção
BR0015875A (pt)	2000-05-10	2003-06-24	Mayo Foundation	Anticorpos igm humano com a capacidade de induzir remielinização, e usos diagnósticos e terapêutico dos mesmos, particularmente no sistema nervoso central
US20040142325A1 (en) *	2001-09-14	2004-07-22	Liat Mintz	Methods and systems for annotating biomolecular sequences
AU2004247021A1 (en)	2003-05-16	2004-12-23	Acorda Therapeutics	Compositions and methods including a recombinant human MAB that promotes CNS remyelination
EP2481750A1 (en) *	2004-06-30	2012-08-01	Mayo Foundation for Medical Education and Research	B7-DC binding antibody
US20060099203A1 (en) *	2004-11-05	2006-05-11	Pease Larry R	B7-DC binding antibody
US7645575B2 (en) *	2004-09-08	2010-01-12	Xdx, Inc.	Genes useful for diagnosing and monitoring inflammation related disorders
DE602005027258D1 (de) *	2005-03-14	2011-05-12	Us Gov Health & Human Serv	Humane monoklonale antikörper gegen hendra- und nipah-viren
RU2448979C2 (ru) *	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
US8728477B2 (en) *	2007-09-19	2014-05-20	Immune Pharmaceuticals Ltd.	Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof
WO2009052374A2 (en) *	2007-10-18	2009-04-23	Mayo Foundation For Medical Education And Research	Igm-mediated receptor clustering and cell modulation
US8013125B2 (en) *	2008-03-03	2011-09-06	Dyax Corp.	Metalloproteinase 9 and metalloproteinase 2 binding proteins
ES2793008T3 (es) *	2008-06-25	2020-11-12	Novartis Ag	Anticuerpos estables y solubles que inhiben VEGF
CN104725507B (zh) *	2010-10-19	2018-12-21	梅奥医学教育和研究基金会	用于治疗神经疾病的人抗体及其诊断和治疗用途

2011
- 2011-10-19 CN CN201510019719.4A patent/CN104725507B/zh not_active Expired - Fee Related
- 2011-10-19 AU AU2011318567A patent/AU2011318567B2/en not_active Ceased
- 2011-10-19 CN CN201180061125.XA patent/CN103429260B/zh not_active Expired - Fee Related
- 2011-10-19 NZ NZ624752A patent/NZ624752A/en not_active IP Right Cessation
- 2011-10-19 CA CA2815046A patent/CA2815046C/en active Active
- 2011-10-19 ES ES11834753.3T patent/ES2662100T3/es active Active
- 2011-10-19 CA CA3037903A patent/CA3037903A1/en active Pending
- 2011-10-19 BR BR112013009673-0A patent/BR112013009673B1/pt not_active IP Right Cessation
- 2011-10-19 NZ NZ609607A patent/NZ609607A/en not_active IP Right Cessation
- 2011-10-19 EP EP17205247.4A patent/EP3345619A1/en not_active Withdrawn
- 2011-10-19 WO PCT/US2011/001773 patent/WO2012054077A2/en active Application Filing
- 2011-10-19 US US13/880,415 patent/US20130280167A1/en not_active Abandoned
- 2011-10-19 EP EP11834753.3A patent/EP2629795B1/en active Active
- 2011-10-19 JP JP2013534892A patent/JP6000959B2/ja not_active Expired - Fee Related
2013
- 2013-04-18 IL IL225837A patent/IL225837B/en active IP Right Grant
2015
- 2015-12-11 HK HK15112222.8A patent/HK1211593A1/xx not_active IP Right Cessation
2016
- 2016-04-08 JP JP2016077993A patent/JP2016130259A/ja not_active Withdrawn
2017
- 2017-05-03 AU AU2017202957A patent/AU2017202957B2/en not_active Ceased
2018
- 2018-03-19 JP JP2018051084A patent/JP6768728B2/ja not_active Expired - Fee Related
- 2018-09-13 IL IL261742A patent/IL261742B/en active IP Right Grant
2019
- 2019-01-10 HK HK19100399.6A patent/HK1258028A1/zh unknown
2020
- 2020-05-07 US US16/869,344 patent/US20200397898A1/en not_active Abandoned
- 2020-05-22 JP JP2020089544A patent/JP2020141696A/ja not_active Withdrawn
2022
- 2022-04-04 JP JP2022062441A patent/JP2022091948A/ja active Pending

Also Published As

Publication number	Publication date
AU2017202957A1 (en)	2017-05-25
IL261742A (en)	2018-10-31
CA3037903A1 (en)	2012-04-26
EP2629795A2 (en)	2013-08-28
EP2629795B1 (en)	2017-12-06
JP2022091948A (ja)	2022-06-21
CN104725507B (zh)	2018-12-21
JP6768728B2 (ja)	2020-10-14
JP2014504263A (ja)	2014-02-20
CA2815046A1 (en)	2012-04-26
CA2815046C (en)	2019-05-14
CN103429260B (zh)	2016-08-10
JP6000959B2 (ja)	2016-10-05
BR112013009673B1 (pt)	2022-05-17
NZ609607A (en)	2014-12-24
AU2011318567B2 (en)	2017-02-09
JP2018099130A (ja)	2018-06-28
JP2016130259A (ja)	2016-07-21
EP3345619A1 (en)	2018-07-11
BR112013009673A2 (pt)	2021-02-02
IL261742B (en)	2020-03-31
US20200397898A1 (en)	2020-12-24
JP2020141696A (ja)	2020-09-10
WO2012054077A3 (en)	2013-10-31
IL225837A0 (en)	2013-07-31
AU2011318567A1 (en)	2013-05-23
CN103429260A (zh)	2013-12-04
HK1258028A1 (zh)	2019-11-01
NZ624752A (en)	2015-11-27
CN104725507A (zh)	2015-06-24
AU2017202957B2 (en)	2019-06-06
IL225837B (en)	2018-10-31
WO2012054077A2 (en)	2012-04-26
ES2662100T3 (es)	2018-04-05
EP2629795A4 (en)	2015-03-04
US20130280167A1 (en)	2013-10-24

Publication	Publication Date	Title
HK1258028A1 (zh)	2019-11-01	人類抗體及其在神經疾病治療中的診斷和治療用途
HUS2400027I1 (hu)	2024-08-28	Rekombináns humán G-CSF dimer és alkalmazása, neurológiai betegségek kezelésében
HK1163500A1 (en)	2012-09-14	Pharmaceutical composition for the treatment of heart diseases
PT2642962T (pt)	2016-08-31	Aparelho de massagem do corpo humano ou animal
IL216509A0 (en)	2012-02-29	Use of an anti-tau ps422 antibody for the treatment of brain diseases
EP2621499A4 (en)	2014-04-09	METHODS OF TREATING ALLERGIC DISEASES
HK1178074A1 (en)	2013-09-06	Compositions and methods for the diagnosis and treatment of tumor
HK1169455A1 (zh)	2013-01-25	阿爾茨海默病的診斷和治療
EP3628326C0 (en)	2024-02-28	METHODS AND MATERIALS FOR THE TREATMENT OF POMPE DISEASE
HK1215787A1 (zh)	2016-09-15	用於治療疼痛的藥物組合
IL260078B (en)	2020-10-29	Therapy used to treat Gaucher disease
WO2012044472A9 (en)	2012-06-14	Long term vagal nerve stimulation for therapeutic and diagnostic treatment
GB0906159D0 (en)	2009-05-20	Drug combination for the treatment of proteostatic diseases
EP2563395A4 (en)	2013-11-27	TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES
IL213703A (en)	2016-08-31	Compounds for the treatment of pain and other diseases
GB201021397D0 (en)	2011-01-26	Diagnosis of Crohn's disease
GB2458868A8 (en)	2009-11-04	Treatment of protein aggregation diseases
EP2470268A4 (en)	2012-12-26	PURING-ORIENTED DIAGNOSIS AND THERAPY OF WOUNDS
HK1203190A1 (en)	2015-10-23	Compounds for use in imaging, diagnosing and or treatment of diseases of the central nervous system
IL217133A0 (en)	2012-02-29	Diagnosis and treatment of autoimmune demyelinating diseases
HU0900195D0 (en)	2009-06-29	Diagnosis and treatment of gluten-induced autoimmune diseases
EP2588866A4 (en)	2014-01-22	DIAGNOSIS AND TREATMENT OF BRAIN TUMORS
DK2665746T3 (en)	2021-02-01	Antibodies against the s100p protein for the treatment and diagnosis of cancer
ZA201306759B (en)	2014-05-28	Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system
GB201018362D0 (en)	2010-12-15	Treatment of dupuytren's disease

Legal Events

Date	Code	Title	Description
2024-05-17	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20231023